Onvatilimab, referred to as JNJ-61610588, represents a novel therapeutic antibody aimed at {PD-1 | the PD-1 protein) and currently undergoing evaluation for various {cancer | malignant diseases ) uses . This designed IgG4 monoclonal antibody shows significant potential in blocking PD-1 interaction with its partners, thus activating immune cell reac